The biopharma giant is offering $250,000 in prizes for the best ones
Metastatic breast cancer is incurable, but Pfizer believes there’s much that can be done in the care and treatment of patients who have it.
The biopharma giant is currently running a contest seeking tech-enabled solutions for patients living with the disease. Open to developers, entrepreneurs, designers, and health-care professionals around the globe, the Advancing mBC Patient Care Challenge wants ideas for improving the emotional and physical effects of the disease, quality of life, support networks, and access to information for patients and caregivers.
Applications are due by Jan. 20, 2017.
The contest is a partnership between Pfizer and health-care innovation group Health 2.0. The groups are offering a total of $250,000 in prize funding, with the grand winner receiving $100,000.
Metastatic breast cancer, or mBC, describes the stage at which the tumor has spread beyond the breast to other organs in the body. It kills more than half a million of women – and some men – around the world each year.
Though the median survival for mBC is an estimated two to three years, some patients can live with the disease for several years longer. The indefinite prognosis can lead to high levels of emotional uncertainty for the patients and their families.
In March 2016, Pfizer Oncology conducted one of the most far-reaching analyses on mBC to date. In the report’s foreword, breast cancer researcher Dr. Fatima Cardoso says there are “major shortcomings in the treatment and management of mBC.”
“Unfortunately, we – the breast cancer medical community – have not made the progress that my colleagues and I would like to see in treating this disease,” she writes, adding that the industry’s research strategies need a comprehensive overhaul.
Pfizer Announces Expansion of ASPIRE Awards Program for 2017 to Include $5.5M in Funding for Breast and Hematologic Cancers
Pfizer Inc. (NYSE:PFE) today announced that it will expand the company’s Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) program in 2017 to award up to $5.5 million (USD) in new competitive grants to fund research studies involving Pfizer products in both breast and hematologic cancers. This expanded program will be known as the ASPIRE Oncology/Hematology Clinical Research Awards.
“We look forward to enhancing this important grants program in 2017 to further support investigator-initiated efforts in both breast and hematologic cancers where there is a substantial need for research that may lead to improved care,” said Graciela Mabel Woloj, PhD, senior director, Medical Affairs, Pfizer Oncology. “Supporting research projects that advance medical and scientific knowledge about our therapies is at the cornerstone of our commitment to meeting the needs of the cancer community.”
Investigators in the United States are encouraged to submit proposals for innovative clinical research that evaluates select Pfizer compounds and that is aimed at advancing knowledge in the treatment and disease management of breast cancer as well as hematologic malignancies. Proposals should include IBRANCE® (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, for metastatic breast cancer, the most advanced stage of breast cancer (stage IV); Mylotarg (gemtuzumab ozogamicin), an investigational antibody-drug conjugate (ADC) targeting CD33, for acute myeloid leukemia (AML),,the most common leukemia in adults; and inotuzumab ozogamicin, an investigational ADC targeting CD22, for acute lymphoblastic leukemia (ALL), a rapidly progressing blood cancer with the lowest five-year survival rate among all leukemias.
Pfizer also announced the 2016 ASPIRE Breast Cancer Research Award recipients, who were selected through a competitive application process overseen by an independent review panel of breast cancer experts. Four grants totaling more than $3 million in funding were awarded to investigators in the United States in support of clinical research projects investigating IBRANCE. The following investigators and studies have been awarded grants:
- Drs. Ingred Mayer and Carlos Arteaga, Vanderbilt University School of Medicine – Phase Ib trial of Fulvestrant, Palbociclib (CDK 4/6 Inhibitor) and Erdafitinib (JNJ-42756493, pan-FGFG tyrosine kinase inhibitor) in ER+/HER2-/FGFR- amplified metastatic breast cancer.
- Dr. Amy Tiersten, Mount Sinai School of Medicine – Multicenter, Phase I/II Trial of Arimidex, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
- Drs. Elena Shagisultanova and Virginia Borges, University of Colorado-Denver – Phase Ib/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of ONT-380 in Combination with Palbociclib and Letrozole in Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer
The $5.5 million (USD) allocated for the 2017 ASPIRE Oncology/Hematology Clinical Research Awards will fund six to eight studies. The proposal submission period ends March 31, 2017. For more information about the 2017 ASPIRE Oncology/Hematology Clinical Research Awards and to submit your proposal, please visit www.aspireresearch.org(link is external
About Pfizer Oncology
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people’s lives.
Pfizer Inc.: Working together for a healthier worldTM
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com.